Any current/future capex/capital investment/strategic investment?

Current quarter CAPEX was about Rs. 80 crores. CAPEX for the rest of the year is expected to remain in a similar range (around Rs. 80 crores per quarter). Investments are focused on Brownfield facilities and new facilities like Whitefield and North Bangalore. Additional ROU of Rs. 200 crores related to new facilities in Ahmedabad and North Bangalore added. Post-acquisition of Vizag-based Mahatma Gandhi Hospital, no immediate additional equipment CAPEX planned, as the hospital is well-equipped (robotic unit, PET scan, linear accelerators). A new linear accelerator is being added to the Vizag ce

Any current/future new fundraising through debt or equity?

Post-acquisition of Vizag, the company's debt will initially increase by Rs. 200 crores and later by another Rs. 150 crores after 18 months to complete an 85% acquisition. The management plans to seek board approval at the appropriate time for a primary equity raise ("primary"), aimed at significantly reducing debt. The exact size of the primary equity raise will be communicated when finalized. The company intends to maintain its debt-to-equity ratio within internally accepted ranges, targeting a debt-to-EBITDA ratio of around 2.5x to 2.75x on a pre-Ind AS basis. Currently, there are no mature

Future growth expectations in sales/revenue/volumes?

Q1 FY25 revenue at an all-time high of Rs. 526 crore, reflecting 17% growth YoY (adjusted for discontinued centers). Established centers, excluding fertility business, grew 18% YoY with strong volume growth and improved realization. Early Q2 performance strong, expected 14-15% growth QoQ, led by operational leverage. Anticipated ongoing 13-15% revenue growth in existing hospitals for full year. International business doubled compared to pre-COVID levels; focus on expanding markets in SAARC, Middle East, and Africa. Acquisition of MG Hospital (Vizag) expected to boost consolidated rev

Future growth expectations in earnings/operating earnings/profits/EPS?

Q1 FY25 showed strong performance with 17% revenue growth (adjusted) and 21% Adj. EBITDA growth. Established centers grew revenue by 14% YoY; emerging centers grew 33% YoY in Q1. MG Hospital acquisition in Vizag (85% stake) with 35% EBITDA margin added to future growth. EBITDA margin expected near 20% for established businesses excluding acquisitions. EBITDA margins and profits to improve as emerging centers mature and operating leverage increases. PAT for Q1 was Rs. 12 crores, up 59% YoY; expected to improve gradually as subsidiaries turn profitable and benefit from better tax rates. Early Q2

Current/ Expected Orderbook/ Pending Orders?

The transcript provided does not explicitly mention the current or expected order book or pending orders for HealthCare Global Enterprises Limited. The discussion primarily focuses on financial performance, operational highlights, acquisitions (such as Vizag-based MG Hospital acquisition), CAPEX plans, debt management, and growth outlook. There is no direct reference to specific order book details, contracts in hand, or pending orders within the provided pages. For precise order book or pending orders information, please refer to the company's official financial disclosures or investor relatio

IN US

Sale is live|00:00:00left today

Healthcare Global Enterprises LtdQ2 FY24Healthcare Services

Healthcare Global Enterprises Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹612P/E: 314.2Market Cap: ₹8.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Q1 FY25 revenue at an all-time high of Rs. 526 crore, reflecting 17% growth YoY (adjusted for discontinued centers).
→Established centers, excluding fertility business, grew 18% YoY with strong volume growth and improved realization.
→Early Q2 performance strong, expected 14-15% growth QoQ, led by operational leverage.
→Anticipated ongoing 13-15% revenue growth in existing hospitals for full year.
→International business doubled compared to pre-COVID levels; focus on expanding markets in SAARC, Middle East, and Africa.
→Acquisition of MG Hospital (Vizag) expected to boost consolidated revenue, expanding market share to 46% in region with 10-12% expected growth.
→Emerging centers growing rapidly at 33% YoY; established centers growing at 14% YoY.
→Improvements in Average Length of Stay (ALOS) and ARPOB (up 12% YoY) supporting volume and revenue expansion.
→Expansion through Brownfield and new facilities, with CAPEX around Rs. 80 crores per quarter to support growth.

Margin guidance

Category 1

→Q1 FY25 showed strong performance with 17% revenue growth (adjusted) and 21% Adj. EBITDA growth.
→Established centers grew revenue by 14% YoY; emerging centers grew 33% YoY in Q1.
→MG Hospital acquisition in Vizag (85% stake) with 35% EBITDA margin added to future growth.
→EBITDA margin expected near 20% for established businesses excluding acquisitions.
→EBITDA margins and profits to improve as emerging centers mature and operating leverage increases.
→PAT for Q1 was Rs. 12 crores, up 59% YoY; expected to improve gradually as subsidiaries turn profitable and benefit from better tax rates.
→Early Q2 indications are positive, expecting ~15% YoY revenue growth and Rs. 100 crore+ EBITDA.
→Debt to EBITDA targeted at 2.5x to 2.75x, with plans for equity raising to reduce debt and improve capital structure.
→Revenue growth trajectory expected at 13-15% for established hospitals full-year basis.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Post-acquisition of Vizag, the company's debt will initially increase by Rs. 200 crores and later by another Rs. 150 crores after 18 months to complete an 85% acquisition.
→The management plans to seek board approval at the appropriate time for a primary equity raise ("primary"), aimed at significantly reducing debt.
→The exact size of the primary equity raise will be communicated when finalized.
→The company intends to maintain its debt-to-equity ratio within internally accepted ranges, targeting a debt-to-EBITDA ratio of around 2.5x to 2.75x on a pre-Ind AS basis.
→Currently, there are no mature inorganic acquisition opportunities under evaluation, but the company continues to assess strategic inorganic options.
→CAPEX funding partly involves debt; Rs. 50 crores of the Rs. 80 crores CAPEX in Q1 was funded through debt, contributing to increased finance costs.
→Overall, a primary equity raise is planned in the medium term to manage leverage following recent acquisitions.

Order book

→The transcript provided does not explicitly mention the current or expected order book or pending orders for HealthCare Global Enterprises Limited.
→The discussion primarily focuses on financial performance, operational highlights, acquisitions (such as Vizag-based MG Hospital acquisition), CAPEX plans, debt management, and growth outlook.
→There is no direct reference to specific order book details, contracts in hand, or pending orders within the provided pages.
→For precise order book or pending orders information, please refer to the company's official financial disclosures or investor relations communications beyond this transcript.

Capex plans

Yes

→Current quarter CAPEX was about Rs. 80 crores.
→CAPEX for the rest of the year is expected to remain in a similar range (around Rs. 80 crores per quarter).
→Investments are focused on Brownfield facilities and new facilities like Whitefield and North Bangalore.
→Additional ROU of Rs. 200 crores related to new facilities in Ahmedabad and North Bangalore added.
→Post-acquisition of Vizag-based Mahatma Gandhi Hospital, no immediate additional equipment CAPEX planned, as the hospital is well-equipped (robotic unit, PET scan, linear accelerators).
→A new linear accelerator is being added to the Vizag center as part of the CAPEX.
→Company aims to optimize operational efficiencies and synergies across hospitals to drive growth and cost management.

How does Healthcare Global Enterprises Ltd rank vs peers in Healthcare Services?

Pro feature

1Healthcare Global Enterprises Ltd

Rev 3Mar 1

See full Healthcare Services sector rankings

Want more stocks like Healthcare Global Enterprises Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio